Guardant Reveal™
Minimal residual disease (MRD) detection for early-stage cancer surveillance
Guardant Reveal™ is a blood-based ctDNA test used after curative-intent treatment to assess minimal residual disease (MRD) and monitor for molecular recurrence over time. It combines epigenomic (methylation) and genomic signal detection to improve sensitivity without requiring tumor tissue for assay design.
For appropriate patients, results can support post-treatment risk stratification, adjuvant therapy discussions, and longitudinal surveillance planning. Clinical interpretation should always be integrated with stage, pathology, imaging, and multidisciplinary clinical judgment.
- Oncologists caring for patients after curative-intent therapy who need ctDNA-based MRD or recurrence-risk assessment.
- Teams planning adjuvant treatment discussions where earlier molecular risk information may be useful.
- Longitudinal surveillance programs that track molecular changes over time.
- Cases where a tissue-free approach is preferred or tissue is limited.
- Not a standalone diagnostic test for initial cancer detection in asymptomatic individuals.
- Not a replacement for pathology, imaging, endoscopy, or other guideline-directed assessments.
- Not intended to independently determine treatment decisions without clinical context.
- Not a direct substitute for physician judgment in post-treatment management.
>20,000 epigenomic signals
| Step / Test | Accuracy | Notes |
|---|---|---|
| Longitudinal Sensitivity | 81% | COSMOS (COnquer Solid Malignancies by blOod Screening) study |
| Specificity | 98% | COSMOS (COnquer Solid Malignancies by blOod Screening) study |
2 × 10ml Streck Cell-Free DNA BCT® tubes
- 20 mL peripheral blood collected into 2 × Streck Cell-Free DNA BCT® tubes.
- Collected by a licensed healthcare professional.
Use manufacturer-specified collection tubes and shipping procedures. Samples should be packaged and transported per current Guardant instructions to preserve ctDNA integrity and ensure valid processing.
Samples must be collected and submitted through an authorised healthcare provider.
- Collect blood into Streck Cell-Free DNA BCT® tubes (room-temperature stable up to 14 days).
- Do NOT centrifuge. Ship tubes intact at ambient temperature; avoid freezing or >37°C.
- Include completed test requisition form. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong.
Please contact us for pricing.
- Positive ctDNA/MRD indicates molecular evidence of residual or recurrent disease risk and should trigger context-specific clinical assessment.
- Negative ctDNA/MRD lowers but does not eliminate recurrence risk. Serial trend dynamics should be interpreted with staging, pathology, imaging, and clinical course.
ctDNA-based MRD testing can provide orthogonal molecular evidence of residual cancer risk and can precede radiographic recurrence in some patients.
A tissue-free workflow can streamline serial testing across follow-up timepoints. Evidence and reimbursement support are strongest in colorectal cancer contexts, while use in other settings should follow local policy, available evidence, and clinician judgment.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
